Will kratom produce a false-positive buprenorphine result on a urine drug screen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Kratom Does Not Cause False-Positive Buprenorphine Results on Standard UDS

Kratom will not produce a false-positive result for buprenorphine on standard urine drug screens. These are chemically distinct substances with different metabolic pathways that do not cross-react on immunoassay testing.

Why This Matters

Kratom contains alkaloids (primarily mitragynine and 7-hydroxymitragynine) that act on opioid receptors but have completely different chemical structures from buprenorphine 1. Standard immunoassay drug screens detect specific drug metabolites through antibody binding, and the structural differences between kratom alkaloids and buprenorphine prevent cross-reactivity.

What Actually Causes False-Positive Buprenorphine Results

The evidence identifies specific substances that can cause false-positive buprenorphine screens:

  • Tramadol: Multiple studies confirm tramadol can cause false-positive buprenorphine immunoassays, particularly with certain assay types (CEDIA at 5 ng/mL cutoff) 2
  • Loperamide (Imodium): At high concentrations (>12.2 mg/L), the metabolite N-desmethyl loperamide can produce false-positive buprenorphine results on CEDIA assays 3
  • High-dose opiates: Opiate concentrations >2000 µg/L can cause cross-reactivity with CEDIA buprenorphine immunoassays 4

Kratom is notably absent from this list despite extensive literature on drug testing interference 1.

Clinical Implications for Kratom Testing

If you need to detect kratom use, understand these key points:

  • Kratom requires specialized testing: Standard drug panels do not detect kratom alkaloids 5
  • Specific kratom metabolite testing is necessary: Gas chromatography-mass spectrometry (GC-MS) targeting mitragynine metabolites (16-carboxy-mitragynine, 9-O-demethyl-mitragynine) is required 5
  • Detection window varies: Kratom metabolites can be detected in urine, but timing depends on dose, plant type, and individual metabolism 5

Important Caveats

Confirmatory testing is essential when buprenorphine immunoassay results don't match clinical presentation 1. False-positives occur with screening immunoassays due to cross-reactivity, but confirmatory testing (GC-MS or LC-MS/MS) is highly specific and will differentiate true buprenorphine from interfering substances 1.

If a patient reports kratom use and has a positive buprenorphine screen, consider:

  • Concurrent buprenorphine use (kratom users may use buprenorphine for kratom withdrawal 6, 7, 8)
  • Presence of tramadol or loperamide 3, 2
  • Request confirmatory testing to resolve the discrepancy

The bottom line: A positive buprenorphine screen in a kratom user indicates either true buprenorphine use or interference from a different substance—not kratom itself.

Related Questions

Does ketamine produce a positive result for buprenorphine on a standard urine drug screen?
What is the appropriate initial dose of buprenorphine/naloxone (Suboxone) for managing kratom withdrawal?
What is the recommended buprenorphine dosing and taper schedule for managing kratom withdrawal?
In a 33-year-old male on extended-release buprenorphine/naloxone (Brixadi) who is actively using alcohol and kratom (mitragynine 20 ng/mL) and has labs showing glucose 132 mg/dL, BUN 7.8 mg/dL, chloride 97 mmol/L, CO₂ 31 mmol/L, total protein 8.4 g/dL, albumin 5.6 g/dL, cotinine 1609 ng/mL, buprenorphine 121 ng/mL, norbuprenorphine 182 ng/mL, ETG >12500 ng/mL, ETS >5000 ng/mL, sertraline >2500 ng/mL, what is the appropriate management?
What is the appropriate buprenorphine/naloxone induction and dosing schedule for a patient taking 300 mg of kratom daily?
Does the Daytrana (methylphenidate) transdermal patch reduce gastrointestinal upset in patients with attention-deficit/hyperactivity disorder?
Can lamotrigine cause decreased appetite?
Can patients with mast cell activation syndrome (MCAS) safely take Odactra (house dust mite sublingual immunotherapy)?
How should a patient be switched from lumateperone 42 mg daily to quetiapine extended‑release (XR)?
How should I taper off 200 mg of gabapentin (Neurontin) in an adult?
What are the indications and eligibility criteria for the Nidra (Tonic Motor Activation) implant in adults with moderate-to-severe Restless Legs Syndrome refractory to standard pharmacologic therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.